{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:01:22Z","timestamp":1793970082485,"version":"4.8.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bioorg.2025.109157","type":"journal-article","created":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:43:12Z","timestamp":1761493392000},"page":"109157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Design, synthesis, and antitumor evaluation of new pyridazinone scaffolds as dual EGFR\/VEGFR-2 kinase inhibitors and apoptotic cells inducers"],"prefix":"10.1016","volume":"166","author":[{"given":"Sara Y.","family":"Ewieda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman M.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirvana A.","family":"Gohar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaymaa G.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa A.","family":"Essa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed T.M.","family":"Nemr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.bioorg.2025.109157_bb0005","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41571-021-00514-z","article-title":"Planning for tomorrow: global cancer incidence and the role of prevention 2020\u20132070","volume":"18","author":"Soerjomataram","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bioorg.2025.109157_bb0010","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.bioorg.2025.109157_bb0015","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.3390\/cancers13051027","article-title":"A novel bispecific antibody targeting EGFR and VEGFR2 is effective against triple negative breast cancer via multiple mechanisms of action","volume":"13","author":"Mohan","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2025.109157_bb0020","doi-asserted-by":"crossref","first-page":"117751","DOI":"10.1016\/j.ejmech.2025.117751","article-title":"Discovery and optimization of 2-pyridones as dual h-DHFR\/EGFRTK inhibitors with immunomodulatory potential; design, synthesis, anti-proliferative activity, and apoptosis inducer","author":"Ragab","year":"2025","journal-title":"Eur. J. Med. Chem.294"},{"issue":"4","key":"10.1016\/j.bioorg.2025.109157_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-025-02652-1","article-title":"Targeting EGFR and PI3K\/mTOR pathways in glioblastoma: innovative therapeutic approaches","volume":"42","author":"Singh","year":"2025","journal-title":"Med. Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109157_bb0030","first-page":"50","article-title":"Tumor angiogenesis and VEGFR-2: mechanism, pathways and current biological therapeutic interventions","volume":"22","author":"Shah","year":"2021","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.bioorg.2025.109157_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101539","article-title":"TIE2-high cervical cancer cells promote tumor angiogenesis by upregulating TIE2 and VEGFR2 in endothelial cells","volume":"26","author":"Tan","year":"2022","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.bioorg.2025.109157_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128529","article-title":"Novel benzothiazole-based dual VEGFR-2\/EGFR inhibitors targeting breast and liver cancers: synthesis, cytotoxic activity, QSAR and molecular docking studies","volume":"58","author":"Abd El-Meguid","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.bioorg.2025.109157_bb0045","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3390\/molecules26041076","article-title":"Molecular targeting of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR)","volume":"26","author":"Kaufman","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.109157_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2022.115911","article-title":"Ethoxy-erianin phosphate and afatinib synergistically inhibit liver tumor growth and angiogenesis via regulating VEGF and EGFR signaling pathways","volume":"438","author":"Chen","year":"2022","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"10","key":"10.1016\/j.bioorg.2025.109157_bb0055","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.3390\/cells11101694","article-title":"Mediating EGFR-TKI resistance by VEGF\/VEGFR autocrine pathway in non-small cell lung cancer","volume":"11","author":"Osude","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2025.109157_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-021-02130-2","article-title":"Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies","volume":"40","author":"Zhou","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109157_bb0065","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13046-021-01961-3","article-title":"Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma","volume":"40","author":"Sharma","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109157_bb0070","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jtho.2020.10.006","article-title":"Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC","volume":"16","author":"Le","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109157_bb0075","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3892\/ijo.2023.5474","article-title":"Dual inhibition of EGFR-VEGF: an effective approach to the treatment of advanced non-small cell lung cancer with EGFR mutation","volume":"62","author":"Wang","year":"2023","journal-title":"Int. J. Oncol."},{"issue":"4","key":"10.1016\/j.bioorg.2025.109157_bb0080","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3390\/ph18040585","article-title":"Synergizing success: the role of anlotinib combinations in advanced non-small cell lung cancer treatment","volume":"18","author":"Hetta","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioorg.2025.109157_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110001","article-title":"EGFR inhibitor erlotinib plus monoclonal antibody versus erlotinib alone for first-line treatment of advanced non-small cell lung carcinoma: A systematic review and meta-analysis","volume":"119","author":"Liu","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"6","key":"10.1016\/j.bioorg.2025.109157_bb0090","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3390\/ph14060589","article-title":"Potentiating therapeutic effects of epidermal growth factor receptor inhibition in triple-negative breast cancer","volume":"14","author":"You","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"4","key":"10.1016\/j.bioorg.2025.109157_bb0095","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3390\/cancers13040634","article-title":"Anticancer therapy with HDAC inhibitors: mechanism-based combination strategies and future perspectives","volume":"13","author":"Jenke","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2025.109157_bb0100","doi-asserted-by":"crossref","first-page":"117847","DOI":"10.1016\/j.bmc.2024.117847","article-title":"Recent contributions of pyridazine as a privileged scaffold of anticancer agents in medicinal chemistry: an updated review","author":"Liu","year":"2024","journal-title":"Bioorg. Med. Chem.111"},{"issue":"6","key":"10.1016\/j.bioorg.2025.109157_bb0105","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jhet.4589","article-title":"Pyridazinones: A versatile scaffold in the development of potential target-based novel anticancer agents","volume":"60","author":"Singh","year":"2023","journal-title":"J. Heterocyclic Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2025.109157_bb0110","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1039\/D4MD00481G","article-title":"Pyridazinone-based derivatives as anticancer agents endowed with anti-microbial activity: molecular design, synthesis, and biological investigation","volume":"15","author":"El-Nagar","year":"2024","journal-title":"RSC Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109157_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.22173","article-title":"Pyridazine and pyridazinone derivatives: synthesis and in vitro investigation of their anti-inflammatory potential in LPS-induced RAW264. 7 macrophages","volume":"85","author":"Osman","year":"2024","journal-title":"Drug Devel. Res."},{"issue":"23","key":"10.1016\/j.bioorg.2025.109157_bb0120","doi-asserted-by":"crossref","first-page":"12885","DOI":"10.1080\/07391102.2023.2273985","article-title":"The anticancer and anti-inflammatory activity screening of pyridazinone-based analogs against human epidermoid skin cancer with detailed mechanistic analyses","volume":"42","author":"Bershawy","year":"2024","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109157_bb0125","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3390\/molecules28020678","article-title":"Synthesis, spectroscopic characterization, antibacterial activity, and computational studies of novel pyridazinone derivatives","volume":"28","author":"Daoui","year":"2023","journal-title":"Molecules"},{"issue":"7","key":"10.1016\/j.bioorg.2025.109157_bb0130","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.cpan.2025.08.001","article-title":"Design, synthesis, and therapeutic potential of pyridazinone-based molecules: an updated comprehensive review","volume":"21","author":"El Bouamri","year":"2025","journal-title":"Curr. Pharm. Anal."},{"issue":"21","key":"10.1016\/j.bioorg.2025.109157_bb0135","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.3390\/molecules28217252","article-title":"Nanoparticles of a pyrazolo-pyridazine derivative as potential EGFR and CDK-2 inhibitors: design, structure determination, anticancer evaluation and in silico studies","volume":"28","author":"Hashem","year":"2023","journal-title":"Molecules"},{"issue":"16","key":"10.1016\/j.bioorg.2025.109157_bb0140","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1080\/17568919.2024.2379234","article-title":"An overview of pyridazin-3 (2H)-one: a core for developing bioactive agents targeting cardiovascular diseases and cancer","volume":"16","author":"Abd-Rabo","year":"2024","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109157_bb0145","first-page":"1","article-title":"Design and synthesis of new quinazolinone derivatives conjugated with chalcone or pyridazine moieties: anticancer activities and apoptotic induction","author":"Elazab","year":"2025","journal-title":"Polycycl. Aromat. Compd."},{"issue":"11","key":"10.1016\/j.bioorg.2025.109157_bb0150","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1080\/13543776.2021.1935872","article-title":"An updated patent review of VEGFR-2 inhibitors (2017-present)","volume":"31","author":"Farghaly","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"issue":"45","key":"10.1016\/j.bioorg.2025.109157_bb0155","doi-asserted-by":"crossref","first-page":"33384","DOI":"10.1039\/D4RA05244G","article-title":"Recent updates on potential of VEGFR-2 small-molecule inhibitors as anticancer agents","volume":"14","author":"Chaudhari","year":"2024","journal-title":"RSC Adv."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109157_bb0160","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/jama.298.1.70","article-title":"Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas","volume":"298","author":"Karamouzis","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.bioorg.2025.109157_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112946","article-title":"Pyridazine as a privileged structure: an updated review on anticancer activity of pyridazine containing bioactive molecules","volume":"209","author":"He","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2025.109157_bb0170","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s12032-023-02174-8","article-title":"Single-cell transcriptomic analysis reveals crucial oncogenic signatures and its associative cell types involved in gastric cancer","volume":"40","author":"Sekaran","year":"2023","journal-title":"Med. Oncol."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109157_bb0175","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/cbdd.13801","article-title":"Recent advances in Bcr-Abl tyrosine kinase inhibitors for overriding T315I mutation","volume":"97","author":"Liu","year":"2021","journal-title":"Chem. Biol. Drug Des."},{"issue":"6","key":"10.1016\/j.bioorg.2025.109157_bb0180","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1039\/D3RA07280K","article-title":"Exploring the untapped pharmacological potential of imidazopyridazines","volume":"14","author":"Malik","year":"2024","journal-title":"RSC Adv."},{"issue":"6","key":"10.1016\/j.bioorg.2025.109157_bb0185","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/14656566.2025.2487150","article-title":"Efficacy and safety of taletrectinib for treatment of ROS1 positive non-small cell lung cancer: a systematic review","volume":"26","author":"Khan","year":"2025","journal-title":"Expert Opin. Pharmacother."},{"issue":"6","key":"10.1016\/j.bioorg.2025.109157_bb0190","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-21-2997","article-title":"ATR inhibitor AZD6738 (ceralasertib) exerts antitumor activity as a monotherapy and in combination with chemotherapy and the PARP inhibitor olaparib","volume":"82","author":"Wilson","year":"2022","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109157_bb0195","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1080\/14756366.2019.1651723","article-title":"Towards discovery of novel scaffold with potent antiangiogenic activity; design, synthesis of pyridazine based compounds, impact of hinge interaction, and accessibility of their bioactive conformation on VEGFR-2 activities","volume":"34","author":"Jaballah","year":"2019","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109157_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.107062","article-title":"Iodoquinazoline-derived VEGFR-2 and EGFRT790M dual inhibitors: design, synthesis, molecular docking and anticancer evaluations","volume":"143","author":"Mohamed","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109157_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.107037","article-title":"Identification of novel ureido benzothiophenes as dual VEGFR-2\/EGFR anticancer agents","volume":"143","author":"Eldehna","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109157_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107403","article-title":"Discovery of novel pyrazole based urea\/thiourea derivatives as multiple targeting VEGFR-2, EGFRWT, EGFRT790M tyrosine kinases and COX-2 inhibitors, with anti-cancer and anti-inflammatory activities","volume":"147","author":"Fadaly","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109157_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107437","article-title":"Novel quinazolin-2-yl 1, 2, 3-triazole hybrids as promising multi-target anticancer agents: design, synthesis, and molecular docking study","volume":"148","author":"El Hamaky","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109157_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107778","article-title":"Unveiling the anticancer potential of novel spirooxindole-tethered pyrazolopyridine derivatives","volume":"153","author":"Eldehna","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109157_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107817","article-title":"Tetrahydrocarbazoles incorporating 5-arylidene-4-thiazolinones as potential antileukemia and antilymphoma targeting tyrosine kinase and tubulin polymerase enzymes: design, synthesis, structural, biological and molecular docking studies","volume":"153","author":"Ali","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109157_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118348","article-title":"Design and synthesis of new pyridazinone derivatives as selective COX-2 inhibitors: in-vitro and in-vivo evaluation of the anti-inflammatory activity, histopathological studies and molecular modelling","volume":"130","author":"Hassan","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109157_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107623","article-title":"Synthesis, COX-2 inhibition, anti-inflammatory activity, molecular docking, and histopathological studies of new pyridazine derivatives","volume":"150","author":"Ewieda","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2025.109157_bb0240","article-title":"Synthesis, computer aided screening and pharmacological evaluation of 2\/3-substituted-6 (4-methylphenyl)-4,5-dihydropyridazin3 (2H)-ones, and pyridazine substituted triazine","volume":"26","author":"Khokra","year":"2015","journal-title":"Indones. J. Pharm.\/Majalah Farmasi Indonesia"},{"key":"10.1016\/j.bioorg.2025.109157_bb0245","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ejmech.2013.03.066","article-title":"Further studies on 2-arylacetamide pyridazin-3 (2H)-ones: design, synthesis and evaluation of 4, 6-disubstituted analogs as formyl peptide receptors (FPRs) agonists","volume":"64","author":"Giovannoni","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109157_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105325","article-title":"Design, synthesis, biological evaluation, and molecular docking studies of novel pyrazolo [3, 4-d] pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers","volume":"116","author":"Sherbiny","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109157_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117005","article-title":"Design, synthesis, and cytotoxicity screening of novel pyrazolopyrimidines over renal cell carcinoma (UO-31 cells) as p38\u03b1 inhibitors, and apoptotic cells inducing activities","volume":"281","author":"Ewieda","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109157_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104134","article-title":"New fused pyrimidine derivatives with anticancer activity: synthesis, topoisomerase II inhibition, apoptotic inducing activity and molecular modeling study","volume":"103","author":"Nemr","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109157_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104446","article-title":"Design, synthesis and antiproliferative evaluation of new tricyclic fused thiazolopyrimidines targeting topoisomerase II: molecular docking and apoptosis inducing activity","volume":"105","author":"Nemr","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109157_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.134216","article-title":"Design, synthesis and chemoinformatic studies of new thiazolopyrimidine derivatives as potent anticancer agents via phosphodiesterase-5 inhibition and apoptotic inducing activity","volume":"1272","author":"Nemr","year":"2023","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2025.109157_bb0275","doi-asserted-by":"crossref","first-page":"108694","DOI":"10.1016\/j.bioorg.2025.108694","article-title":"Synthesis and apoptotic induction of sulfonamide-based chalcone hybrids as first-in-class dual histone deacetylase-carbonic anhydrase inhibitors with potential anti-tubulin activity","volume":"163","author":"Mohamed","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109157_bb0280","doi-asserted-by":"crossref","first-page":"108672","DOI":"10.1016\/j.bioorg.2025.108672","article-title":"Discovery of novel thiazolopyrimidine derivatives targeting topoisomerase II: design, synthesis, antiproliferative evaluation, molecular docking and apoptosis inducing activity","volume":"163","author":"Ewieda","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109157_bb0285","doi-asserted-by":"crossref","first-page":"108563","DOI":"10.1016\/j.bioorg.2025.108563","article-title":"Design and synthesis of new pyrazole hybrids linked to oxime and nitrate moieties as COX-2, EGFRL858R\/T790M inhibitors and nitric oxide donors with dual anti-inflammatory\/anti-proliferative activities","volume":"161","author":"Fadaly","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109157_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107622","article-title":"Design, synthesis and cytotoxic evaluation of new thieno [2, 3-d] pyrimidine analogues as VEGFR-2\/AKT dual inhibitors, apoptosis and autophagy inducers","volume":"150","author":"Abd El-Mawgoud","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109157_bb0295","article-title":"New pyrazolyl-thiazolidinone\/thiazole derivatives as celecoxib\/dasatinib analogues with selective COX-2, HER-2 and EGFR inhibitory effects: design, synthesis, anti-inflammatory\/anti-proliferative activities, apoptosis, molecular modelling and ADME studies","volume":"38","author":"Fadaly","year":"2023","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109157_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104473","article-title":"Development of pyridazine derivatives as potential EGFR inhibitors and apoptosis inducers: design, synthesis, anticancer evaluation, and molecular modeling studies","volume":"106","author":"Ahmed","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109157_bb0305","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ejmech.2015.11.042","article-title":"Pyridazinone derivatives displaying highly potent and selective inhibitory activities against c-Met tyrosine kinase","volume":"108","author":"Liu","year":"2016","journal-title":"Eur. J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2025.109157_bb0310","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1021\/acs.jmedchem.1c01714","article-title":"Development of dual inhibitors targeting epidermal growth factor receptor in cancer therapy","volume":"65","author":"Tan","year":"2022","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2025.109157_bb0315","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1634\/theoncologist.2008-0276","article-title":"Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC","volume":"14","author":"Pennell","year":"2009","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.bioorg.2025.109157_bb0320","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.14534","article-title":"Structural and molecular insights from dual inhibitors of EGFR and VEGFR2 as a strategy to improve the efficacy of cancer therapy","volume":"103","author":"Budipramana","year":"2024","journal-title":"Chem. Biol. Drug Des."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109157_bb0325","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2024.2367128","article-title":"Fluorinated indeno-quinoxaline bearing thiazole moieties as hypoglycaemic agents targeting \u03b1-amylase, and \u03b1-glucosidase: synthesis, molecular docking, and ADMET studies","volume":"39","author":"Gohar","year":"2024","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109157_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108218","article-title":"Novel pyrrolidine-bearing quinoxaline inhibitors of DNA gyrase, RNA polymerase and spike glycoprotein","volume":"156","author":"Ebrahim","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109157_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107410","article-title":"Novel guanidine derivatives targeting leukemia as selective Src\/Abl dual inhibitors: design, synthesis and anti-proliferative activity","volume":"147","author":"Moustafa","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109157_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107881","article-title":"Novel benzenesulfonamide derivatives as potential selective carbonic anhydrase IX, XII inhibitors with anti-proliferative activity: design, synthesis and in silico studies","volume":"153","author":"Fadaly","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109157_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107566","article-title":"Design, synthesis, antineoplastic activity of new pyrazolo [3, 4-d] pyrimidine derivatives as dual CDK2\/GSK3\u03b2 kinase inhibitors; molecular docking study, and ADME prediction","volume":"150","author":"Nemr","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109157_bb0350","volume":"38","author":"Fadaly","year":"2023","journal-title":"J. Enzyme Inhib. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825010375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825010375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T19:06:07Z","timestamp":1763665567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825010375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":70,"alternative-id":["S0045206825010375"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109157","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and antitumor evaluation of new pyridazinone scaffolds as dual EGFR\/VEGFR-2 kinase inhibitors and apoptotic cells inducers","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109157","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109157"}}